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Summary
As a leading cause of childhood mortality worldwide, selection pressure by
Plasmodium falciparum continues to shape the human genome. Severe dis-
turbances within the microcirculation result from the adhesion of infected
erythrocytes to host receptors on monocytes, platelets, and endothelium. In
this prospective study, we compared expression of all major host cytoadhe-
sion receptors among Ugandan children presenting with uncomplicated
malaria (n = 1078) versus children with severe malaria (n = 855), including
cerebral malaria (n = 174), severe anaemia (n = 522), and lactic acidosis
(n = 154). We report a signiﬁcant survival advantage attributed to blood
group O and increased monocyte expression of CD36 and ICAM1 (CD54).
The high case fatality rate syndromes of cerebral malaria and lactic acidosis
were associated with high platelet CD36 expression and thrombocytopenia,
and severe malaria anaemia was characterized by low ICAM1 expression. In
a logistic regression model of disease severity, odds ratios for the mitigating
effects of blood group O, CD36, and ICAM1 phenotypes were greater
than that of sickle haemoglobin. Host genetic adaptations to Plasmodium
falciparum suggest new potential malaria treatment strategies.
Keywords: Malaria, ABO, Anaemia, Platelet, CD36, ICAM1.
Although the human genome has been remarkably altered by
selective pressure from malaria (Weatherall, 2008), infection
with Plasmodium falciparum continues to kill large numbers
of children born within malaria endemic regions character-
ized by limited health resources (World Health Organization
[WHO], 2011). Prior to developing adaptive immunity and
gaining access to therapy, malaria-infected children depend
upon host attributes that optimize parasite clearance or miti-
gate lethal pathophysiology (Stevenson & Riley, 2004). The
best appreciated adaptations to P. falciparum, such as sickle
haemoglobin and thalassaemia, appear to be concerned not
with invasion resistance, but rather with earlier clearance of
infected erythrocytes (iRBC) within the spleen as a result of
modiﬁed red cell ﬁtness (Modiano, 1998). Furthermore, the
most lethal malaria syndromes appear to associate with
enhanced iRBC adhesion (Miller et al, 2002; Rowe et al,
2009a), wherein parasite trafﬁc to the spleen is reduced by
systemic (“extrasplenic”) sequestration of iRBC. Although
favourable to survival of the parasite, adhesion and seques-
tration of iRBC result in microvascular obstruction and
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research papertissue hypoperfusion in the host (van der Heyde et al, 2006).
Whether human hosts show any evidence of reduced or dif-
ferential expression of adhesion receptors (Cserti-Gazdewich
et al, 2011) as a counter-adaptation to iRBC cytoadhesion
has not been fully investigated and is the focus of this study.
The most appealing candidates for possible co-evolution
are host receptors of adhesion with P. falciparum Erythrocyte
Membrane Protein (PfEMP-1) (Cooke et al, 2004). In labo-
ratory studies, erythrocytes expressing blood group A1, the
primordial human ABO type (Calafell et al, 2008), exhibit
strong rosette formation through binding of the lectin-like
domain of PfEMP-1 (Carlson & Wahlgren, 1992; Vigan-
Womas et al, 2012), while the evolutionarily more recent
group O erythrocytes rosette least (Rowe et al, 2007).
PfEMP-1 contains alternative domains that bind the host
receptors ICAM1 (CD54) and CD36. It has been proposed
that their expression on monocytes may beneﬁt the host by
mediating immune clearance of iRBCs (McGilvray et al,
2000; Baratin et al, 2007). However, ICAM1 and CD36 are
also expressed on endothelial cells, promote adhesion of
iRBC to the vasculature (Yipp et al, 2000), and therefore
may be detrimental to the host. The biology of sequestration
via CD36 is further complicated by its expression on platelets
(as platelet glycoprotein IV). Platelets expressing CD36 may
mediate microvascular occlusion either by facilitating clump-
ing of iRBC (Pain et al, 2001) or by bridging adhesion of
iRBC to endothelial cells (Bridges et al, 2010).
Consistent with human-parasite co-evolution, prior studies
have observed a higher ratio of blood group O-to-A (Cserti
& Dzik, 2007) and a higher prevalence of ICAM1 (Fernandez-
Reyes et al, 1997) and CD36 (Gelhaus et al, 2001; Fry et al,
2009) mutations among individuals who reside in areas
endemic for P. falciparum. However, prior clinical studies
have either examined cytoadhesion receptors individually,
not accounted for the effect of other clinical risk factors, or
have had small sample sizes. As a result, the relative contri-
bution of the major host cytoadhesion receptors to malaria
pathogenesis has remained incompletely characterized (Rowe
et al, 2009b; Ochola et al, 2011).
To test the hypothesis that host blood cell phenotypes are
associated with malaria severity, we conducted the Cytoad-
herence in Paediatric Malaria (CPM) Study in a cohort of
two thousand children in Uganda. We compared expression
of the major host cytoadhesion receptors across a spectrum
of malaria severity, quantiﬁed their relative effect size com-
pared with other recognized factors that inﬂuence severity
(such as sickle trait), and examined their distributions in
three severe malaria syndromes.
Methods
Study population
This prospective case-control study enrolled children, age
6 months to 12 years, presenting with either initially severe
or uncomplicated P falciparum malaria to Mulago Hospi-
tal’s Acute Care Unit in meso-endemic Kampala, Uganda
between October 15, 2007 and October 30, 2009. Children
with severe malnutrition were ineligible for enrolment. The
malaria diagnosis was established ﬁrst with clinical symp-
toms and a positive screening thick smear. Two blinded
reviewers of thin and thick smears at a reference parasitol-
ogy laboratory independently conﬁrmed the diagnosis and
parasite density using leucocyte counts (Figs 1–2i n
supporting information).
Oversight
Approval for the study was granted by Makerere University
Faculty of Medicine Research Ethics Committee, the Toronto
Academic Health Science Network Research Ethics Board,
and the Uganda National Council for Science and Technol-
ogy. The study was registered as NCT 00707200 at www.
clinicaltrials.gov.
Consent form
The consent form was available in both English and Luganda
and was approved by research ethicists in Toronto, Canada
and Kampala, Uganda, in accordance with Good Clinical
Practice Guidelines. The research ofﬁcers, ﬂuent in both lan-
guages, were trained in the administration and documenta-
tion of informed consent from the parents or legal guardians
of paediatric subjects. Parents/guardians retained a copy of
consent forms with supplementary study summary pamphlets
and investigator contact information.
Data collection
Each enrolled patient was evaluated and treated by physicians
experienced in malaria care, using all available clinical
resources to assess the presence of other conditions. Data
were recorded on a hard-copy Case Report Form (CRF),
available at www.cd36malaria.org. After each subject’s dis-
charge, data were transferred to a digital CRF. Regular fort-
nightly conference calls (n = 55) reviewed logistics, tabulated
accrual statistics, and monitored study quality control. The
accuracy of data transfer to the digital CRF was audited on
each 25th CRF quarterly. The digital CRF (prepared in File-
Maker Pro 90 v 1, Santa Clara, CA, USA) mirrored the
paper CRF with multiple features to prevent transcription
errors. Paper and digital CRFs were kept in a secure, locked
environment during enrollment and transferred at the con-
clusion of enrollment to study headquarters for use in reso-
lution of any discrepancies in the database.
The electronic study database, prepared from exports of the
digital CRF, underwent extensive testing for data integrity,
consistency, and accuracy. Scrutiny included range value test-
ing, missing data testing, logical tests on data consistency
across ﬁelds, and multiple comparisons with the original paper
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were done on a single version of a ﬁnalized corrections dataset.
Clinical procedures and categorization
Patients were observed until discharge or death by two study
physicians. Prior to analysis, each patient was categorized at
ﬁnal disposition as a case or control, and if failing to meet
pre-speciﬁed deﬁnitions, was excluded. Controls were those
with uncomplicated malaria (UM), deﬁned as the absence of
any impairment of consciousness or hypoxia, with peripheral
blood lactate <5 mmol/l and haemoglobin (Hb) >70 g/l
without transfusion. Cases were those with severe malaria
(SM) including severe malaria anaemia (SMA), deﬁned as
Hb < 50 g/l (or <60 g/l after transfusion); lactic acidosis
(LA), deﬁned as blood lactate >5 mmol/l; hypoxia, deﬁned
as oxygen saturation <90% while breathing ambient air; or
cerebral malaria (CM), as deﬁned below.
Deﬁnition of cerebral malaria (CM)
WHO guidelines provide general criteria to characterize cere-
bral malaria, i.e., Blantyre Coma Scale (BCS) 2 with
depressed levels or loss of consciousness (LOC) persisting
>1 h after any possible prior convulsions (Idro et al, 2005).
Due to recent evidence for the non-speciﬁcity of WHO criteria
for CM when compared with autopsy conﬁrmation or expert
retinoscopy (Taylor et al, 2004), and because the neurological
literature on LOC has established that prolonged post-ictal
states and/or anticonvulsants may themselves affect level of
consciousness, we opted for a stricter screening deﬁnition of
CM that accepted coma under the following conditions:
1 Coma was present for more than 6 h, particularly if
following convulsions, and
2 Coma was not attributable to high fevers, hypoglycaemia,
meningitis, non-malaria-related pre-existing neurological
abnormalities, or drugs, such as anticonvulsants or other
agents with sedative/hypnotic effects (WHO, 1986).
To increase the speciﬁcity of our categorization of CM
cases, we used objective clinical criteria that included both
WHO features of severe disease, and a case report form-
derived scoring system. A case was designated as probable to
deﬁnite CM (n = 174) if the patient had coma plus >3o f
the following 10 WHO malaria severity criteria: >2 seizures
in 24 h, respiratory distress, jaundice, haemoglobinuria,
spontaneous bleeding, hypoglycaemia (glucose < 22 mmol/l),
lactic acidosis (lactate >5 mmol/l), normocytic severe anaemia,
hyperparasitaemia >5%, or new acute renal failure; or if the
patient had a cumulative score of 3 points (n = 169) using
the following scale:
1 Coma:
1 point: survivor with timing of coma to seizures not
speciﬁed.
2 points: fatal case with timing of coma to seizures not
speciﬁed.
3 points: coma present >6 h after last seizure.
2 Blantyre Score <3:
1 point: survivor with timing of Blantyre score to seizures
not speciﬁed.
2 points: fatal case with timing of Blantyre score to sei-
zures not speciﬁed.
3 points: score <3 and performed >6 h after last seizure.
3 Seizures witnessed in hospital:
1 point: survivor with 3 observed seizures (or number
not recorded) in 24 h.
2 points: fatality with 3 observed seizures (or number
not reported) in 24 h.
6 points: >3 observed seizures in 24 h.
4 Blood sugar:
0 points: blood sugar not tested at time of coma or Blan-
tyre assessment.
0 points: blood sugar 3 mmol/l at time of coma or
Blantyre score assessment.
1 point: blood sugar <3 mmol/l at time of coma or
Blantyre score assessment.
5 Lumbar puncture (performed in n = 56):
0 points: not performed.
1 point: performed and did not show signs of meningitis.
6 Retinoscopy (performed in n = 12):
0 points: if negative or not performed.
2 points: if positive.
Laboratory procedures
Patients were excluded if human immunodeﬁciency virus
(HIV) positive. 740 patients were tested for HIV in Kampala
using a screening assay (Clearview
® STAT-PAK
®, Inverness
Medical, Louisville CO, USA). Negative screening tests were
re-tested with a second assay (Uni-Gold
TM Recombigen
®
HIV, Trinity Biotech PLC, Wicklow, Ireland), and positive
screening tests conﬁrmed with a second enzyme-linked assay
(Murex HIV Ag/Ab Combination; Abbott Diagnostics Divi-
sion, Dartford, UK; or Vironistika
® HIV Uni-Form II Ag/Ab;
bioMe ´rieux, Lyon, France). Archived plasma aliquots from
the remaining 1331 who were not tested in Kampala (or not
already excluded) were tested with a high-sensitivity com-
mercial assay for antigen and antibody at Mount Sinai Hos-
pital’s Microbiology Laboratory in Toronto, Canada
(Architect System HIV Ag/Ab Combo; Abbott Diagnostics
Division, Weisbaden, Germany). 45 HIV+ subjects were
excluded from analysis. Of the 733 subjects identiﬁed as
HIV-negative by laboratory testing in Kampala, 05% of
ABO, CD36, and ICAM1 in Malaria
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the negative result.
ABO blood groups were determined locally on peripheral
blood collected in EDTA- anticoagulated tubes. ABO Blood
Group Reagents (Anti-A BioClone
®, Anti-B BioClone
®, Anti-
D for Slide and Modiﬁed Tube Tests, ORTHO
® Anti-A1
Lectin; Ortho-Clinical Diagnostics, Inc, Raritan, NJ, USA)
were applied to whole blood for direct haemagglutination
typing according to manufacturer’s directions.
Monocyte CD54, monocyte CD36, and platelet CD36 were
determined in a blinded fashion by ﬂow cytometry (Joint
Clinical Research Centre, Kampala) according to previously
published methods established for malaria patients (Cserti-
Gazdewich et al, 2009, 2010; Dzik et al, 2010) measuring
median ﬂuorescence intensity (MFI) (Fig 3 in supporting
information). Values for monocyte CD36 MFI were corrected
for the effect of platelet count prior to analysis (Dzik et al,
2010). Complete blood counts were determined by Coulter
AC*T8 (Coulter Corp, Miami, FL, USA). Peripheral blood
lactate was measured with a point-of-care device (Lactate-
Pro, Arkray Inc, Kyoto, Japan). Oxygen saturation was mea-
sured by ﬁnger oximetry (Nonin Corp, Plymouth, MN,
USA). The presence of haemoglobin S (HbS) was detected by
solubility (SickleDex
®, Streck Laboratories, Omaha, NB,
USA).
Statistical analysis
Continuous data are reported as a median with inter-quartile
ranges, and compared using a Wilcoxon test with a = 005.
Categorical data were compared using the chi-square test
with a = 005. All comparisons were two tailed.
Logistic regression was used to measure factors associated
with severe malaria. Input variables in the model were age,
sex, presence of haemoglobin S, leucocyte count, platelet
count, presence of hyperparasitaemia, ABO group, monocyte
CD54, monocyte CD36 and platelet CD36 (Table I in sup-
porting information). Because group A and AB individuals
strongly express the A antigen, they were entered together in
the model. Because CD36 and CD54 MFI approximate a
log-normal distribution (Fig 4 in supporting information),
log-transformed values were entered in the model. Odds
ratios (OR) and signiﬁcance were computed using commer-
cial software (Stata
® ver 11.1; Stata Corp, College Station,
TX, USA).
The study was powered to detect a difference in the
proportion of cases with blood group A or AB compared
with the proportion of controls with group A or AB.
Assuming a baseline prevalence of group A or AB ranging
from 025 to 04, our study, with approximately 1000 cases
and 1000 controls, could detect a 6% or greater difference
in the proportion of group A or AB among cases versus
controls with at least 80% power and a type I error prob-
ability of 005.
Results
Patients
A total of 2092 patients were enrolled, with 81 exclusions (45
HIV+, 35 falsely positive for P falciparum, 1 not of predeﬁned
age-range). Of the 2011, 78 were excluded from analysis
because at ﬁnal disposition, they did not meet pre-study deﬁ-
nitions of uncomplicated malaria (UM) or severe malaria
(SM). Controls included UM outpatients (UM-o, n = 316,
291%) and UM inpatients (UM-i, n = 762, 394%). Cases
comprised SM survivors (SM-s n = 807, 417%) and fatalities
(SM-f, n = 48, 56%) (Fig 1A). Median hospital length of stay
was 2, 3 and 1 d among UM-i, SM-s and SM-f, respectively.
Illness in the great majority was attributable exclusively to
malaria rather than to other infections. None of the 56 lum-
bar punctures in suspected cases of cerebral malaria showed
meningitis. In four chest radiographs of suspected pneumo-
Enrolled, n = 2092
Exclusions, n = 81
Not meeting definition of
control or case, n = 78
Fatal
malaria in-
patient
n = 48 
Severe malaria 
survivor
in-patient
n = 807 
Uncomplicated
malaria
in-patient
n = 762 
Uncomplicated
malaria
out-patient
n = 316 
Analysis, n = 1933
Cases,
n = 855
Controls,
n = 1078
154
Cerebral
(B)
(A)
malaria (CM) 
Severe malaria
anaemia (SMA)
Lactic acidosis (LA)
n = 174 n = 558
n = 482
CM+  (n = 174)
SMA+ CM–  (n = 522)
LA+ SMA– CM–  (n = 154)
274
248
12
24
56
82
Fig 1. Study design and patient categories. (A) Pre-speciﬁed catego-
ries of patients enrolled. The analysis of severity of disease compares
controls (uncomplicated malaria, UM, n = 1078) with cases (severe
malaria, SM, n = 855). (B) Distribution of the three principal severe
malaria syndromes among the cases. For analysis, cases are classiﬁed
into three non-overlapping categories: all cerebral malaria (CM)
(grey); severe malaria anaemia (SMA) without CM (white); and iso-
lated lactic acidosis (LA) not attributable to SMA or CM (black).
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British Journal of Haematology, 2012, 159, 223–236nia, only one showed inﬁltrates. Parenteral antibiotics were
empirically offered in one case of unconﬁrmed meningitis
and 38 cases of unconﬁrmed pneumonia.
Table I compares baseline patient features between UM
and SM. Children with UM and SM had similar sex ratios
and prevalence of haemoglobin S (HbS). Cases were signiﬁ-
cantly younger, had a lower body mass index, had been
unwell for longer before hospital presentation, and had a
greater extent of palpable splenomegaly. Although median
parasitaemia was similar in cases and controls, hyperparasita-
emia (>5% of erythrocytes parasitized) was present twice as
often among cases (48% vs. 25%). Median (interquartile
range) parasitaemia in children positive for HbS was half
that of children negative for HbS [44 200 (16 800–141 000)
vs. 88 400 (27 400–216 000), P = 00031]. As shown in
Table I, SM was also characterized by lower platelet counts, a
higher prevalence of severe thrombocytopenia, and higher
leucocyte and monocyte counts.
SM cases reﬂected severe malaria anaemia (SMA,
n = 558), lactic acidosis (LA, n = 482), and cerebral malaria
(CM, n = 174) with some expected overlap (Fig 1B).
Hypoxia was present in 43 children and was the only SM
manifestation in ﬁve. For the analysis of SM syndromes in
Table I and Fig 1–5, SM cases were classiﬁed into three non-
overlapping groups as follows: all CM (n = 174); SMA with
or without LA (SMA, n = 522); and isolated LA without
either SMA or CM (isolated LA, n = 154), Table I, Fig 1B.
Because we hypothesize that SMA is a syndrome character-
ized by less receptor-dependent microvascular occlusion than
the syndromes of CM and isolated LA, these severe syn-
dromes were compared accordingly. SMA patients were sig-
niﬁcantly younger, had evidence of greater splenomegaly,
and a lower burden of parasitaemia (Table I). In contrast,
children with CM or isolated LA had lower platelet, leucocyte
and monocyte counts, and higher blood lactate levels. The
case fatality rate (CFR) was nearly ten-fold higher for those
with CM compared with SMA (19% vs. 2%, P < 00001).
ABO blood group
The distribution of ABO types varied substantially between
UM vs. SM, v
2 = 2957, P < 00001. Group A or AB preva-
lence was 91% higher in SM (371%) compared with UM
(280%), P < 00001; while group O prevalence was 93%
higher in UM (499%) compared with SM (406%),
P < 00001. This was further reﬂected in a consistent gradient
of changing ABO proportions across severity subgroups
(UM-o, UM-i, SM-s, SM-f) (Fig 2A). Group A or AB was
more likely than group O to have a fatal versus uncompli-
cated outcome [OR = 227, 95% conﬁdence interval (CI)
121–428, P = 0047]. In logistic regression analysis, group A
or AB remained signiﬁcantly associated with SM (OR = 150,
95% CI 12–21, P = 00008) after controlling for the effect of
age, gender, HbS, platelet count, leucocyte count, hyperpara-
sitaemia, monocyte CD54, monocyte CD36 and platelet CD36
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Fig 2. ABO blood groups in patients with malaria. (A) ABO groups
according to the spectrum of disease severity. Controls have a higher
prevalence of group O, and cases have a higher prevalence of non-
group O. (B) ABO distributions among the cases (severe or fatal
malaria) are signiﬁcantly different from that observed in healthy
adult Ugandan blood donors. (C) Among group A or AB cases, A1
positive cases are more likely to have CM or LA than those negative
for A1. UM-o, uncomplicated malaria treated as an outpatient; UM-i,
uncomplicated malaria treated as an inpatient. SM-s, severe malaria,
survivor; SM-f, severe malaria, fatal; SMA, severe malaria anaemia;
LA, lactic acidosis; CM, cerebral malaria.
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British Journal of Haematology, 2012, 159, 223–236(Fig 3). The ABO distribution was also vastly different
between enrolled children with SM (Table I) and the 180 000
healthy adults who donated blood in 2008 to the nationalized
Uganda Blood Transfusion Service (A: 249%, B: 209%, AB:
45%, O: 497%; personal communication, Dr Dorothy Kye-
yune, Nakasero Blood Transfusion Service) (Fig 2B).
The distribution of ABO groups remained signiﬁcantly
different in SM for SMA versus non-SMA cases (v
2 = 1036,
P < 00157) (Fig 2A). Although the proportion of group O
patients did not vary within the three SM subgroups, (40%,
42%, 40%), the non-O distributions consisted of more group
A patients among those with CM or isolated LA versus SMA
(339% vs. 268%, P = 0033), and correspondingly more
group B (B or AB) among those with SMA [328%
(234% + 94%) vs. 251% (205% + 46%), P = 0021].
When group A or AB cases were further sub-classiﬁed
according to the presence or absence of the A1 antigen, a lar-
ger proportion of the patients with CM or isolated LA were
represented among those positive for A1 (P = 0016, Fig 2C).
The A1 antigen was present in 979% of non-SMA subjects,
while A1-negative variants were present in a 5-fold higher
proportion (114%) in SMA (OR 599, 95% CI 135–2656)
(Table II in supporting information).
Monocyte CD54 (ICAM1)
Monocyte levels were signiﬁcantly higher in SMA compared
with the other severe malaria syndromes, P < 00001 (Fig 4A).
Median monocyte CD54 (ICAM1) expression per cell was sig-
niﬁcantly lower in SMA compared with other SM syndromes
(P < 00001) or in cases compared with controls (P < 00001)
(Fig 4B).
Risk Factor  P-value
Hyper-parasitaemia P<0·001
N = 1777 
X2 = 571
P < 0·0001
WBC count P<0·001
Ln Plt CD36  P = 0·095
Group B  P = 0·13 
P<0·001 Age
Female P = 0·43 
Platelet count P<0·001
Ln Mono CD54  P<0·001
Hb S  P = 0·46 
Group A or AB  P<0·001
Ln Mono CD36  P =0·002
OR (95% CI) 
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Fig 3. Factors associated with uncomplicated or severe malaria.
Results of logistic regression model showing the odds ratios (OR,
black circles) and 95% conﬁdence intervals (95% CI, horizontal
lines) for uncomplicated versus severe or fatal malaria according to
input risk factors. Odds ratios for age are scaled per year and for
white blood cell count (WBC) and platelet count (Plt) are scaled in
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9/l and 10 9 10
9/l, respectively. Mono, monocyte;
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Fig 4. Monocyte CD54 and CD36 expression in patients with
malaria. (A) The median and inter-quartile range of monocyte
counts is shown. (B) The median and inter-quartile range of
CD54 (ICAM1) expression on monocytes (measured as median
ﬂuorescence intensity using ﬂow cytometry). Low monocyte CD54
expression is seen among cases with SMA. (C) The median and
inter-quartile range of CD36 expression on monocytes (measured as
median ﬂuorescence intensity using ﬂow cytometry). A progressive
decline in monocyte CD36 expression is associated with categories
of increasing disease severity. UM-o, uncomplicated malaria treated
as an outpatient; UM-i, uncomplicated malaria treated as an inpa-
tient; SM-s, severe malaria; survivor. SM-f, severe malaria, fatal;
SMA, severe malaria anaemia; LA, lactic acidosis; CM, cerebral
malaria.
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Monocyte CD36 levels were signiﬁcantly higher in UM versus
SM (P < 00001) (Fig 4C). Among cases, however, median
monocyte CD36 values did not differ by syndromes. Platelet
CD36 expression, in contrast, did not differ between SM and
UM, but was signiﬁcantly higher among those with CM or iso-
lated LA compared with SMA (P = 00009), (Fig 5A). Given
higher relative monocyte CD36 in UM and higher relative plate-
let CD36 in non-SMA, the monocyte-to-platelet CD36 ratio best
accounted for the differential tissue expression effects of CD36
(Fig 5B). This ratio decreased in proportion with increasing dis-
ease severity (P < 00001), and with CM and isolated LA.
ThrombocytopeniaisrecognizedbytheWHOasamanifesta-
tion of severe malaria (WHO, 2000). The present study
conﬁrmed this association (Table I) and further found that
platelet counts were signiﬁcantly lower in syndromes associated
with cytoadhesion (CM and isolated LA) compared with SMA
(Fig 5C). We found that the relationship between platelet CD36
expression and platelet count, reﬂecting CD36 expression per
platelet, varied with both severity and syndrome type. UM-o
patients had the highest platelet counts with lowest observed
plateletCD36expression;whereas CM andisolatedLA hadlow-
est platelet counts with highest platelet CD36 expression
(Fig 5D).
Host receptor phenotypes in fatal and uncomplicated
malaria
Table II compares host receptor phenotypes between children
with fatal or uncomplicated malaria outcomes. The preva-
lence of group A or AB was signiﬁcantly higher (479% vs.
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Fig 5. CD36 Expression and platelet count in patients with malaria. (A) The median and inter-quartile range of platelet CD36 expression (mea-
sured as median ﬂuorescence intensity through ﬂow cytometry) is shown. (B) A progressive decline in the median and inter-quartile range of the
loge of the ratio of monocyte-to-platelet CD36 expression according to disease severity is shown. (C) Increasing disease severity and cases of CM
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patient; UM-i, uncomplicated malaria treated as an inpatient; SM-s, severe malaria, survivor; SM-f, severe malaria, fatal; SMA, severe malaria
anaemia; LA, lactic acidosis; CM, cerebral malaria.
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ICAM1 and CD36 expression were signiﬁcantly higher in
UM compared with SM-f (P < 00001).
Discussion
This prospective study of P. falciparum infection demon-
strated a relationship between the expression of host recep-
tors for ligands of cytoadhesion and disease severity. The
malarial syndromes marked most by hypoperfusion, namely
CM and LA, are of particular signiﬁcance owing to their
unrivalled case fatality rates (Marsh et al, 1995). Cytoadhe-
sion results in sequestration and rosetting of iRBCs (Ho
et al, 1991; Pongponratn et al, 1991; Silamut et al, 1999;
Doumbo et al, 2009), impaired microvascular perfusion, and
endothelial damage (van der Heyde et al, 2006). Despite par-
asiticides, cytoadhesion continues until iRBC structures are
cleared (Hughes et al, 2010). We studied children because of
their higher relative risk of fatal outcomes, their compara-
tively less-developed adaptive immunity, and their least-
selected distribution of severity-mitigating traits on initial
presentation. Our hypothesis was focused not on the absence
or presence of malaria (in the matter of its invasion), but on
host factors associated with clinical severity.
Factors associated with mortality prior to reproductive age
are those most likely to shape the human genome. While
previous studies (Table III in supporting information) (Rowe
et al, 2007; Fry et al, 2008) have suggested an association
between ABO and severity, we document for the ﬁrst time
an increased odds ratio of death associated with A or AB
types, providing clinical evidence to substantiate malaria as
an evolutionary driver of human ABO blood group distribu-
tions (Cserti & Dzik, 2007). We found the relative risk of
fatal malaria to UM was 23-fold higher for group A or AB
versus group O. Among SM cases, the ratio of A to B types
was 15-fold higher in the syndromes of CM and isolated LA
when compared with SMA. We also identiﬁed for the ﬁrst
time that group A1 (the wild-type with the highest A antigen
expression (Berneman et al, 1991)) was over-represented in
the severe malaria syndromes of CM and isolated LA. We
propose that genetic selection against the primordial A1 anti-
gen results in enrichment for either group O in association
with UM, or for weaker non-A1 types or group B in associa-
tion with syndromes such as SMA.
This study is novel for the simultaneous analysis of the
major malaria cytoadhesion receptors found on erythrocytes,
leucocytes, and platelets together with established clinical fac-
tors across a spectrum of disease severity. In a logistic regres-
sion model, the odds ratio for the harm of blood group A or
AB or the beneﬁt of group O remained signiﬁcant even after
controlling for numerous clinical factors including HbS
(Fig 3). Consistent with prior reports on its protective effect
(Aidoo et al, 2002; Williams et al, 2005; Jallow et al, 2009;
Bougouma et al, 2012; Gong et al, 2012), we observed signif-
icantly lower levels of parasitaemia in those with HbS. How-
ever, perhaps due to the low overall prevalence of HbS in
our study population, the proportion of HbS-positive
patients was not signiﬁcantly different in UM vs. SM. In
addition, our study design focused on malaria severity, and
excluded uninfected controls or asymptomatic parasitaemia.
Prior reports have highlighted the role of HbS during these
earlier stages of infection (Gong et al, 2012), which our study
was not designed to assess. For example, Crompton et al
(2008) concluded that the presence of HbS was associated
with delayed onset of disease, and Verra et al (2007) pro-
posed that the protective effect of HbS was related to
enhanced innate immunity, while Gong et al (2012) inferred
both innate and acquired immunity played age-dependent
protective roles. Other studies have discovered that the pro-
tective effects of HbS may also result from mechanisms
including, but not limited to, cytoadhesion (Cholera et al,
2008; Ferreira et al, 2011).
That malaria is likely to be changing global distributions of
ABO types (Cserti & Dzik, 2007; Cserti-Gazdewich et al,
2011) is supported not only by our severity or survival associ-
ations, but also by the large differences noted between our SM
cases and healthy Ugandan adult blood donors. Because the
burden of malaria surged over the last several decades despite
control efforts, nearly all Ugandan blood donors have success-
fully overcome prior and frequent exposures to P. falciparum,
especially in rural areas with higher endemicity than present
in our study. Thus, malaria selection may be a plausible expla-
nation for the shift in ABO distributions that we observed
within a single nation and generation.
ICAM1 is expressed on the endothelium and may serve as
a sequestration receptor for iRBC. The level of expression of
ICAM1 on monocytes has had an uncertain overall role in
malaria. Monocyte ICAM1 may indirectly enhance iRBC
Table II. Host receptor phenotypes in fatal and uncomplicated malaria.
Prevalence in (or value in)
fatal malaria
Prevalence in (or value in)
uncomplicated malaria P-value
Group A or AB 23/48 479% 302/1077 280% 0005
Monocyte CD54: median MFI 196 (95–281) N = 44 290 (189–404) N = 1018 <00001
Monocyte CD36: median MFI 69 (32–160) N = 44 215 (121–340) N = 1031 <00001
Platelet CD36: median MFI 114 (50–222) N = 47 140 (82–215) N = 1046 0148
Loge (monoCD36/pltCD36): median 029 (120 to +030) N = 44 +048 (007 to +095) N = 1030 <00001
MFI, median ﬂuorescence intensity; monoCD36, monocyte CD36; pltCD36, platelet CD36.
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in CM (Stevenson & Riley, 2004; Baratin et al, 2007). We
found a surprising and signiﬁcant association between lower
monocyte ICAM1 expression in SMA compared with other
severe syndromes. This low expression may reﬂect down-reg-
ulation (or inhibition of upregulation) (Skorokhod et al,
2004) of ICAM1 by haemozoin (Schwarzer et al, 1998),
which has been linked to the pathogenesis of SMA (Perkins
et al, 2011). Alternatively, enhanced clearance of monocytes
with high ICAM1 expression may have occurred. Congruent
with data from Kenya (Novelli et al, 2010), we found that
the clinical factors associated with SMA were younger age,
more palpable splenomegaly, and higher monocyte counts.
TheeffectsofCD36inmalariahavelikewisebeenparticularly
controversial. On monocytes, CD36 supports phagocytosis of
iRBC (McGilvray et al, 2000); while on integumentary tissues
(such as the fat or skin), it detains iRBC and may enhance
vector re-transmission. Cytoadhesion in CM has been pro-
posed to result from bridging iRBCs to endothelial cells via
CD36 expression on platelets (Pain et al, 2001; Bridges et al,
2010). For example, Wassmer et al (2004) demonstrated
in-vitro that binding of iRBCs to brain endothelial cells was
mediated by platelets and was CD36-dependent. Because
genetic studies (Fry et al, 2009; Cserti-Gazdewich et al, 2011)
have provided conﬂicting conclusions, we measured CD36
expression phenotypically rather than inferring expression
from genotypes. We demonstrated that monocyte CD36
expression was signiﬁcantly higher in UM versus SM, and
that platelet CD36 expression was signiﬁcantly higher in
severe cytoadhesive syndromes. We suggest that the most
clinically informative measure of CD36 is the ratio of its
monocyte (beneﬁcial) to platelet (harmful) expression, with
ratio values inversely proportional to severity and with low
ratios associated with CM and isolated LA. This is in keeping
with our previously proposed model of the clinical signiﬁ-
cance of CD36 resulting from differential tissue expression
(Cserti-Gazdewich et al, 2011). Genetic alterations assumed
to diminish CD36 expression across tissues may in fact have
inhomogeneous effects, as shown by zygosity studies where
heterozygous deﬁciency resulted in substantially decreased
expression on platelets compared with monocytes (Imai et al,
2002), thus potentially maximizing the beneﬁt of a “carrier”
state for CD36 deﬁciency (Cserti-Gazdewich et al, 2011). As
with HbS in malaria, CD36 polymorphisms may exhibit a
heterozygous advantage.
Thrombocytopenia is a hallmark of Plasmodial infections,
with several mechanisms unique in P. falciparum, including
platelet binding to iRBCs and endothelial cells (de Mast,
2011; de Mast et al, 2010). We conﬁrm an association
between thrombocytopenia and SM, as well as CM and
isolated LA, syndromes speculated to result in part from
cytoadhesion.
The strengths of our study include its mechanism-driven
design of case evaluation, large-volume accrual, completeness
of case reporting, laboratory blinding, and use of validated
assays for host receptors of adhesion ligands. In this largest
prospective study of malaria outcomes according to host
adhesion receptors, limitations nevertheless included: not
characterizing parasite-encoded adhesins or performing adhe-
sion assays with patient-derived iRBC isolates (Ochola et al,
2011); inability to directly measure endothelial ligand expres-
sion; and not having quantiﬁed ICAM1 and CD36 expression
through illness and recovery. We do not yet know which fac-
tors control expression of ICAM1 and CD36, nor how well
their expression on blood cells correlates with endothelial
cells. We therefore cannot conclude whether the observed
relative expression of host receptors of adhesion were the
causes or associated effects of outcomes. Despite attempts to
match UM and SM for age prospectively, while not assessing
for pre-existing humoral malaria immunity, we saw the
expected enrichment of older (and possibly adaptively pro-
tected) children among those with UM. Nevertheless, our
results remained signiﬁcant after adjusting for age. Finally,
the study’s single site location, despite serving as a national
referral centre, may have emphasized adaptations that are
nevertheless regional and not necessarily generalizable to
other malaria-endemic areas.
In summary, we have demonstrated that host phenotypes
for receptors of parasite cytoadhesion ligands associate with
the clinical severity of malaria, as well as with high mortality
manifestations. Speciﬁcally, SMA exhibited low ICAM1
expression, whereas CM or isolated LA demonstrated a high
prevalence of group A1 and an elevated ratio of platelet-to-
monocyte CD36. Informed by the molecular interactions of
parasite and human, the measurable “panel” of ABO type,
monocyte ICAM1 and CD36 expression, and platelet CD36
expression translates clinically. The determination of ABO
type, an unchanging attribute and a categorical measure of
the host, is of particular appeal because of its ease of testing
in resource-limited settings, and its signiﬁcance at the level
of malaria mortality. The observation that ABO is an inde-
pendent risk factor for survival among children with malaria
provides the most compelling explanation to date for evolu-
tion away from the A1 wild-type and towards the weaker
subgroups of A, group B or AB, and most importantly
group O. Finally, these results invite approaches to malaria
treatment that transcend the challenge of developing new
cost-prohibitive drug therapies to which the parasite may
also gain resistance. Re-directing our focus on co-evolution-
ary interactions between host and parasite suggests new lines
of research. For example, the use of “universal” group O
RBCs rather than type-speciﬁc RBCs may prove especially
advantageous for group A1 patients. Because in vitro studies
document that soluble blood group substances can block the
formation of iRBC rosettes (Barragan et al, 2000),
competitive inhibition of cytoadhesion using plasma-sourced
soluble A/B substances or other targeted inhibitors may
merit clinical investigation. Medicine may thus strive to
recapitulate the advantages already gained by natural
selection.
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